Companies
Caris Life Sciences
launched Caris Detect and introduced AI-powered molecular insights for NSCLC patients, alongside AI models predicting brain-metastases risk in breast and lung cancer, its Caris ChromoSeq assay, and its Caris Assure blood-based test.
- Country
- United States
- Ticker
- CAI
Commercial
Caris Detect / Caris Assure / ChromoSeq
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | over 275,000 square feet of space across four laboratories | investor.carislifesciences.com |
| Certification | Rule 13A-14(A)/15D-14(A) and Section 1350 certifications filed with SEC 2026-08-05 | last10k.com |
| Regulatory approval | FDA approval for MI Cancer Seek in November 2024 | carislifesciences.com |
| Regulatory approval | MolDX approval for Caris ChromoSeq as of 2026-08-05 | prnewswire.com |
| Production site | four laboratories spanning over 275,000 square feet | investor.carislifesciences.com |
| Revenue | $263.7 million for the quarter ended June 30, 2026 | carislifesciences.com |
| Revenue | $1.03 billion to $1.04 billion projected for full year 2026 | prnewswire.com |
Independent sources: last10k.com · prnewswire.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-omics diagnostic panels for precision oncology | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.